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Experimental General
Tetraethyl orthosilicate (TEOS, ≥ 99 %), (3-aminopropyl)-triethoxysilane (APTES, ≥ 98 %), ammonium hydroxide (ACS reagent, 28-30 %), ethanol (anhydrous), glutaraldehyde (Grade I, 25 % in water), 6,7dimethoxy-1-methyl-3,4-dihydroisoquinoline, 2-(N-morpholino)ethanesfonic acid, 3-(Nmorpholino)propanesulfonic acid, sodium formate, sodium hydroxide, DCM, isopropanol, diethylamine, DMF, DMSO, N-Boc-ethylenediamine, 4-nitrophenylsulfonyl chloride, diethyl ether, Nmethylmorpholine, 2-chloro-4,6-dimethoxy-1,3,5-triazine, Et 3 N, acetonitrile, [Cp*IrCl 2 ] 2 dimer and NAD + were purchased from commercial suppliers and used without further purification. Mili-Q water (resistivity ≥ 18 MΩ cm -1 ) was produced with a Millipore Synergy purification system. Streptavidin (Sav) mutants were produced, purified and characterized as previously described [1] . 1 H and 13 C spectra were recorded on a Bruker 400 MHz. The chemical shifts (δ) are reported in parts per million (ppm) relative to tetramethylsilane or a residual solvent peak, and the J values are given in Hz. Signals are quoted as s (singlet), d (doublet), t (triplet) and m (multiplet). Analyses of the catalytic runs were performed on an Agilent 1100 normal phase HPLC with an analytical Chiralpak IC column (250 · 4.6 mm, 5 μm). ESI-MS measurements were performed on a Bruker AmaZon TM X. The absorbance spectra were measured on a microplate reader Tecan, model Infinite M200. Nanoparticles were imaged using a Zeiss SUPRA 40VP field emission scanning electron microscope, their size was measured using the acquired micrographs with the Olympus Analysis® software package. ICP-MS analysis was performed on a 7500cx ICP-MS system (Agilent, Basel, Switzerland). 191 Ir was used for quantification, 193 Ir for verification of the results.
Stock solutions and buffers
MOPS/formate buffer: 3-(N-morpholino)propanesulfonic acid and sodium formate were dissolved in Milli-Q water to the concentrations of 6M (formate) and 1.2 M (MOPS). The pH was adjusted to 7 by addition of NaOH.
MES buffer: 2-(N-morpholino)ethanesulfonic acid was dissolved in Mili-Q water to a final concentration of 10 mM. The pH was adjusted to 6.2 by the addition of NaOH.
Activity assay buffer: Sodium formate and K 2 HPO 4 were dissolved in Mili-Q water to a final concentration of 200 mM (formate) and 50 mM (phosphate). The pH was adjusted to 7.5 by addition of NaOH.
Cp*Ir-complexes: [Cp*Ir(biot-p-L)Cl)] was dissolved in DMF to a final concentration of 500 mM. For a detailed synthesis procedure, see reference [2] . [Cp*Ir(4C-L)Cl] was dissolved in DMF to a final concentration of 400 mM.
Substrate: 6,7-dimethoxy-1-methyl-3,4-dihydroisoquinoline 1 was dissolved in Mili-Q water (2 ml) to a final concentration of 1 M.
Synthesis of the non-biotinylated catalyst 10
The synthesis was performed as summarized in following Scheme: 
N-Boc-N'-(4-nitrophenylsulfonyl)-ethylenediamine 5
To a solution of N-Boc-ethylenediamine 4 (1.74 g, 10.8 mmol, 1.0 eq.) and Et 3 N (3 ml, 21.5 mmol, 2.0 eq.) in DCM (300 ml), a solution of 4-nitrophenylsulfonyl chloride 3 (2.51 g, 11.3 mmol, 1.05 eq.) in DCM (100 ml) was added dropwise at 5 °C and stirred overnight. The solution was concentrated to 100 ml, washed with water (3 x 20 ml), and dried over Na 2 SO 4 . The solvent was evaporated under reduced pressure and the crude product was purified by flash chromatography (silicagel, EtOAc : hexane (2 : 3)) The pure product 5 was obtained as a white powder (2.87 g, 8.32 mmol, 77 % yield). 1 
N-Boc-N'-(4-aminophenylsulfonyl)-ethylenediamine 6
An autoclave containing a suspension of Pd/C (5 %, 330 mg) in methanol (20 ml) was charged with N-Boc-N'-(4-nitrophenylsulfonyl)-ethylenediamine 5 (2.10 g, 6.08 mmol). The autoclave was purged three times with nitrogen and filled with hydrogen (3 bars). The reaction was stirred vigorously for 3 hours at RT. The hydrogen pressure was carefully released and the resulting suspension was removed by filtration through a celite plug. The solvent was evaporated under reduced pressure, which yielded product 6 as a white powder (1.78 g, 5.65 mmol, 93 %). 1 
N-Boc-N'-(4-(N'-Boc-4-aminobutanamido)phenylsulfonyl)-ethylenediamine 8
To a suspension of N-Boc-4-aminobutanoic acid 7 (13.2 mg, 0.065 mmol, 1.03 eq.), N-Boc-N '-(4aminophenylsulfonyl)-ethylenediamine 6 (20 mg, 0.063 mmol, 1.0 eq.) and 2-chloro-4,6-dimethoxy-1,3,5-triazine (CDMT) as a coupling agent (11.8 mg, 0.067 mmol, 1.06 eq.) in acetonitrile (10 ml), Nmethylmorpholine (NMM) (9.6 µl, 0.095 mmol, 1.5 eq.) was added. The resulting reaction mixture was stirred at RT for 24 hours and heated to reflux for 6 hours. After cooling the reaction mixture to room temperature, water (3 ml) was added. The solvent was evaporated under reduced pressure. The crude product was purified by flash chromatography (silicagel using EtOAc : n-hexane (2:1)) to obtain the product 8 as a white powder (12.6 mg, 0.025 mmol, 40 % yield). 1 
Synthesis of catalyst [Cp*Ir(4C-L)Cl] 10
The [Cp*IrCl 2 ] 2 dimer (30 mg, 0.038 mmol, 0.475 eq.), the sulfonamide ligand 9 (40 mg, 0.076 mmol, 1 eq.) and Et 3 N (26 µl, 0.19 mmol, 5 eq.) were dissolved in dry DCM (5 ml) under inert atmosphere. After stirring for 24 hours at room temperature, the solution was heated to reflux for 3 hours. The precipitate was filtrated, dissolved in MeOH (1 ml) and precipitated with diethyl ether. The pure catalyst 10 was obtained as a dark orange powder (15 mg, 0.022 mmol, 60 %). 1 
SNPs synthesis
The SNPs were prepared by adapting the procedure described elsewhere [3] as follows. All chemicals and solvents were equilibrated in a water bath (20 °C, 1 h) before use. Ammonium hydroxide (40 ml, 28-30 %) and ethanol (345 ml) were mixed in a round bottom flask (1 l), under stirring (600 rpm). TEOS (15 ml) was added and the solution kept under stirring for 20 h. The resulting milky suspension was centrifuged (3'220 g, 10 min) and the white pellet resuspended in ethanol. This operation (hereafter called 'washing cycle') was repeated once with ethanol and three times with water to yield the SNPs (4 g). Into the stock solution of SNPs in water (18 ml of 3.2 mg·ml −1 ), APTES was added (11 μl , 0.047 mmol) and incubated in a water bath (30 min, 20 °C, 400 rpm). After two washing cycles, the resulting nanoparticles were stored at 4 °C.
All washing steps were performed by centrifugation (3'220 g, 5 min) and the pellets were resuspended by ultrasonic treatment using an ultrasonic bath (2 min).
Sav preincubation and lyophilisation
In a typical experiment, purified Sav mutant (25 mg , approx. 3,8 x 10 -7 mol) was dissolved in water. The average number of free binding sites per purified Sav tetramer was determined with a biotin-4fluorescein assay, as described elsewhere [4] . The corresponding amount of [Cp*Ir(biot-p-L)Cl] ligand stock solution was added to produce protein with binding sites fully filled with the iridium cofactor (ratio of Ir : free binding sites 1 : 1) , or half fulled respectively (ratio of Ir : free binding sites 1 : 2). Samples were incubated (37 °C, 2 h), frozen (-80°C) and lyophilised to dryness. A stock solution (3 mg / ml) was used for protein immobilization.
SNPs synthesis and protection
The aminomodified nanoparticles (15 ml, 3 mg / ml) were incubated (30 min) with aqueous glutaraldehyde solution (60 µl of 25% (v/v)). After two washing cycles with Mili-Q water, the particles were spinned down (3'220 g for 10 min), resuspended in MES buffer (14 ml, 10 mM, pH 6.2) and incubated with the corresponding Sav mutant or iridium catalyst while stirring (1 h, 400 rpm). Subsequently, TEOS was added to the reaction mixture (72 μl, 0.324 mmol) and allowed to react for 1 h. To produce the protected SNPs, the nanoparticles were incubated with APTES (18 μl, 4 , 20°C). Protected nanoparticles were centrifuged (4000 rpm, 5 min) and, after two washing cycles, resuspended in Mili-Q water. The concentration of each SNPs stock solution was determined by freeze-drying of each stock solution (100 μl) and weighted using a microbalance.
Activity assay
In a typical experiment, SNPs (3.2 mg) were resuspended in MES buffer (250 μl, 10 mM, pH 6.2). The solution was mixed with the activity assay buffer (1 : 1 ratio, total V : 400 μl) and NAD + (20 μl, 2 mM stock solution) was added. The reaction medium was then incubated and shaken (30 °C, 1200 rpm). After the desired reaction time (1h), the suspension was centrifuged (16'100 g, 1 min) and the supernatant (70 μl) was collected for UV-Vis analysis on a TECAN plate reader (absorbance spectrum 240 -360 nm).
Bradford assay
A bovine serum albumin standard curve was prepared in buffer (see reference [5] ). 5X Bradford blue reagent (50 µl) was added to a sample or albumin solution (200 µl), mixed and incubated for 5 min at room temperature. The sample was pipetted into a 96-well plate and the absorbance was determined at 595 nm by a spectrophotometer (Synergy™ H1 Hybride reader from BioTek).
Scanning electron microscopy and particle size measurement
Each sample (2 μl) was spread on freshly cleaved mica sheets, dried at room temperature and sputtercoated with a gold-platinum alloy (15 s, 10 mA, SC7620 Sputter coater). Micrographs were acquired using the InLens mode with an accelerating voltage of 20 kV. Particle sizes were measured using the acquired micrographs with the Olympus Analysis® software package. About 100 measurements were recorded per type of nanoparticles. The protective layer thickness was determined by comparing their diameter with the diameter of unprotected native Stöber SNPs. 
ICP-MS determination of the total Ir content
Each type of lyophilized nanoparticles (1 mg) was incubated with NaOH solution (0.5 M, 95°C, 5 min) until complete dissolution [6] . Samples were neutralized using HNO 3 solution (65 %, semiconductor grade, Sigma Aldrich) and diluted using Milli-Q water (final HNO 3 concentration 3 %). Analysis was performed on a 7500cx ICP-MS system (Agilent, Basel, Switzerland) using standard operational settings as described elsewhere [7] . Quantification was perfomed via multi-element standards (Sigma-Aldrich) in matrix-matched calibration solutions containing the same amount of NaOH / HNO 3 as the samples. Rh was used as internal standard to account for residual matrix effects. The octopole was pressurized (4.5 mL · min −1 helium) to remove polyatomic interferences. The reaction was quenched by centrifugation of the reaction mixture (30 s, 3'220 g). The supernatant was collected and the nanoparticle pellet was washed with Mili-Q water (5 x). The joined water phases were basified by addition of NaOH solution (50 µl, 20 % stock solution), extracted with DCM (2 x 0.5 ml), dried over Na 2 SO 4 and analyzed by the means of normal phase HPLC. 
HPLC measurements
Each reaction mixture was analyzed by HPLC using a Chiralpak IC column (5 μm, 4.6 mm · 25 mm) using dichloromethane containing diethylamine (0.06 %) and isopropanol (0.5 %) as an eluent , flow of 1 ml/min; detection at λ=280 nm, 25 °C. T R 8.5 min ((S)-6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline); 9.8 min (6,7-dimethoxy-1methyl-3,4-dihydroisoquinoline); 14.6 min ((R)-6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline; referred to as salsolidine). Yields were calculated using a response factor of 1.95, as determined elsewhere [8] . The reaction was quenched by centrifugation of the reaction mixture. The supernatant was collected and the nanoparticle pellet was washed with Mili-Q water (3 x). The joined water phases were basified by addition of NaOH solution (50 µl, 20 % stock solution), extracted with DCM (2 x 0.5 ml), dried over Na 2 SO 4 and analyzed by the means of normal phase HPLC. Reactions performed in a reaction buffer using 1 mg of SNPs in 100 µl reaction mixture with 20 mM substrate concentration, [b] Enantiomeric excess and conversion was determined by HPLC analysis on a Chiracel-IC column. [c] Positive ee values correspond to (R)-salsolidine; negative ee values correspond to (S)-salsolidine. 
Evolution of enantioselectivity over time

